P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage

CNS Neuroscience and Therapeutics

Volumn 20, Issue 6, 2014, Pages 556-564

  Mesuret, Guillaume ^a   Engel, Tobias ^a   Hessel, Ellen V ^b   Sanz Rodriguez, Amaya ^a   Jimenez Pacheco, Alba ^a   Miras Portugal, M Teresa ^c   Diaz Hernandez, Miguel ^c   Henshall, David C ^a,d  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Apoptosis; Development; Hippocampal sclerosis; Neuroinflammation; Status epilepticus

Indexed keywords

3 [[5 (2,3 DICHLOROPHENYL) 1H TETRAZOL 1 YL]METHYL]PYRIDINE; BUMETANIDE; INTERLEUKIN 1BETA; KAINIC ACID; PHENOBARBITAL; PURINERGIC P2X7 RECEPTOR; 3-(5-(2,3-DICHLOROPHENYL)-1H-TETRAZOL-1-YL)METHYLPYRIDINE; AMINO ACID RECEPTOR STIMULATING AGENT; LOOP DIURETIC AGENT; LUOTONIN B; PURINERGIC P2X RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TETRAZOLE DERIVATIVE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT THERAPY; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; DNA FRAGMENTATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; ELECTROENCEPHALOGRAM; FEMALE; HIPPOCAMPUS; IMMATURITY; IMMUNOREACTIVITY; INFANTILE SPASM; INFLAMMATION; MALE; MOSSY FIBER; NERVE CELL NECROSIS; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PROTEIN BLOOD LEVEL; PYRAMIDAL NERVE CELL; RAT; SEIZURE; TISSUE SECTION; ANIMAL; CELL DEATH; CHEMICALLY INDUCED; DIAGNOSTIC USE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; NEWBORN; PATHOLOGY; SPRAGUE DAWLEY RAT; STATUS EPILEPTICUS; TOXICITY;

AMYGDALA; ANIMALS; ANIMALS, NEWBORN; BUMETANIDE; CELL DEATH; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; FEMALE; HIPPOCAMPUS; KAINIC ACID; MALE; PURINERGIC P2X RECEPTOR ANTAGONISTS; PYRIDINES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STATUS EPILEPTICUS; TETRAZOLES;

EID: 84900547530     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12272     Document Type: Article

References (53)

1. Silverstein FS, Jensen FE. Neonatal seizures. Ann Neurol 2007;62:112-120.
2. Lawrence R, Inder T. Neonatal status epilepticus. Semin Pediatr Neurol 2010;17:163-168.
3. Chin RF, Neville BG, Peckham C, Wade A, Bedford H, Scott RC. Treatment of community-onset, childhood convulsive status epilepticus: A prospective, population-based study. Lancet Neurol 2008;7:696-703.
4. Haut SR, Veliskova J, Moshe SL. Susceptibility of immature and adult brains to seizure effects. Lancet Neurol 2004;3:608-617.
5. Kravljanac R, Jovic N, Djuric M, Jankovic B, Pekmezovic T. Outcome of status epilepticus in children treated in the intensive care unit: A study of 302 cases. Epilepsia 2011;52:358-363.
6. Wirrell EC, Armstrong EA, Osman LD, Yager JY. Prolonged seizures exacerbate perinatal hypoxic-ischemic brain damage. Pediatr Res 2001;50:445-454.
7. Glass HC, Glidden D, Jeremy RJ, Barkovich AJ, Ferriero DM, Miller SP. Clinical neonatal seizures are independently associated with outcome in infants at risk for hypoxic-ischemic brain injury. J Pediatr 2009;155:318-323.
8. Loddenkemper T, Goodkin HP. Treatment of pediatric status epilepticus. Curr Treat Options Neurol 2011;13:560-573.
9. Chapman KE, Raol YH, Brooks-Kayal A. Neonatal seizures: Controversies and challenges in translating new therapies from the lab to the isolette. Eur J Neurosci 2012;35:1857-1865.
10. van Rooij LG, Hellstrom-Westas L, de Vries LS. Treatment of neonatal seizures. Semin Fetal Neonatal Med 2013;18:209-215.
11. Chen JW, Wasterlain CG. Status epilepticus: Pathophysiology and management in adults. Lancet Neurol 2006;5:246-256.
12. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 2008;7:575-590.
13. Coddou C, Yan Z, Obsil T, Huidobro-Toro JP, Stojilkovic SS. Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 2011;63:641-683.
14. Armstrong JN, Brust TB, Lewis RG, MacVicar BA. Activation of presynaptic P2X7-like receptors depresses mossy fiber-CA3 synaptic transmission through p38 mitogen-activated protein kinase. J Neurosci 2002;22:5938-5945.
15. Sperlagh B, Kofalvi A, Deuchars J, et al. Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. J Neurochem 2002;81:1196-1211.
16. Duan S, Anderson CM, Keung EC, Chen Y, Swanson RA. P2X7 receptor-mediated release of excitatory amino acids from astrocytes. J Neurosci 2003;23:1320-1328.
17. Papp L, Vizi ES, Sperlagh B. Lack of ATP-evoked GABA and glutamate release in the hippocampus of P2X7 receptor-/- mice. NeuroReport 2004;15:2387-2391.
18. Cho JH, Choi IS, Jang IS. P2X7 receptors enhance glutamate release in hippocampal hilar neurons. NeuroReport 2010;21:865-870.
19. Monif M, Reid CA, Powell KL, Smart ML, Williams DA. The P2X7 receptor drives microglial activation and proliferation: A trophic role for P2X7R pore. J Neurosci 2009;29:3781-3791.
20. Zou J, Vetreno RP, Crews FT. ATP-P2X7 receptor signaling controls basal and TNFalpha-stimulated glial cell proliferation. Glia 2012;60:661-673.
21. Salas E, Carrasquero LM, Olivos-Ore LA, et al. Purinergic P2X7 receptors mediate cell death in mouse cerebellar astrocytes in culture. J Pharmacol Exp Ther 2013;347:802-815.
22. Matute C, Torre I, Perez-Cerda F, et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 2007;27:9525-9533.
23. Sperlagh B, Vizi ES, Wirkner K, Illes P. P2X7 receptors in the nervous system. Prog Neurobiol 2006;78:327-346.
24. Skaper SD, Debetto P, Giusti P. The P2X7 purinergic receptor: From physiology to neurological disorders. FASEB J 2010;24:337-345.
25. Engel T, Gomez-Villafuertes R, Tanaka K, et al. Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J 2012;26:1616-1628.
26. Jimenez-Pacheco A, Mesuret G, Sanz-Rodriguez A, et al. Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A-438079. Epilepsia 2013;54:1551-1561.
27. Kim JE, Kang TC. The P2X7 receptor-pannexin-1 complex decreases muscarinic acetylcholine receptor-mediated seizure susceptibility in mice. J Clin Invest 2011;121:2037-2047.
28. Henshall DC, Diaz-Hernandez M, Miras-Portugal MT, Engel T. P2X receptors as targets for the treatment of status epilepticus. Front Cell Neurosci 2013;7:237.
29. McGaraughty S, Chu KL, Namovic MT, et al. P2X7-related modulation of pathological nociception in rats. Neuroscience 2007;146:1817-1828.
30. Dunleavy M, Shinoda S, Schindler C, et al. Experimental neonatal status epilepticus and the development of temporal lobe epilepsy with unilateral hippocampal sclerosis. Am J Pathol 2010;176:330-342.
31. Scantlebury MH, Heida JG, Hasson HJ, et al. Age-dependent consequences of status epilepticus: Animal models. Epilepsia 2007;48(Suppl 2):75-82.
32. Clark AK, Staniland AA, Marchand F, Kaan TK, McMahon SB, Malcangio M. P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide. J Neurosci 2010;30:573-582.
33. Raol YH, Lapides DA, Keating JG, Brooks-Kayal AR, Cooper EC. A KCNQ channel opener for experimental neonatal seizures and status epilepticus. Ann Neurol 2009;65:326-336.
34. Cleary RT, Sun H, Huynh T, et al. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS ONE 2013;8:e57148.
35. Ben-Ari Y. Excitatory actions of gaba during development: The nature of the nurture. Nat Rev Neurosci 2002;3:728-739.
36. Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med 2005;11:1205-1213.
37. Pressler RM, Mangum B. Newly emerging therapies for neonatal seizures. Semin Fetal Neonatal Med 2013;18:216-223.
38. Solle M, Labasi J, Perregaux DG, et al. Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 2001;276:125-132.
39. Yu Y, Ugawa S, Ueda T, et al. Cellular localization of P2X7 receptor mRNA in the rat brain. Brain Res 2008;1194:45-55.
40. Engel T, Jimenez-Pacheco A, Miras-Portugal MT, Diaz-Hernandez M, Henshall DC. P2X7 receptor in epilepsy; role in pathophysiology and potential targeting for seizure control. Int J Physiol Pathophysiol Pharmacol 2012;4:174-187.
41. Ferrari D, Chiozzi P, Falzoni S, Hanau S, Di Virgilio F. Purinergic modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin. J Exp Med 1997;185:579-582.
42. Chakfe Y, Seguin R, Antel JP, et al. ADP and AMP induce interleukin-1beta release from microglial cells through activation of ATP-primed P2X7 receptor channels. J Neurosci 2002;22:3061-3069.
43. Dube C, Vezzani A, Behrens M, Bartfai T, Baram TZ. Interleukin-1beta contributes to the generation of experimental febrile seizures. Ann Neurol 2005;57:152-155.
44. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011;7:31-40.
45. Wang X, Arcuino G, Takano T, et al. P2X7 receptor inhibition improves recovery after spinal cord injury. Nat Med 2004;10:821-827.
46. Bernardino L, Balosso S, Ravizza T, et al. Inflammatory events in hippocampal slice cultures prime neuronal susceptibility to excitotoxic injury: A crucial role of P2X7 receptor-mediated IL-1beta release. J Neurochem 2008;106:271-280.
47. Diaz-Hernandez M, Diez-Zaera M, Sanchez-Nogueiro J, et al. Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J 2009;23:1893-1906.
48. Mikati MA, Holmes GL, Chronopoulos A, et al. Phenobarbital modifies seizure-related brain injury in the developing brain. Ann Neurol 1994;36:425-433.
49. Ikonomidou C, Turski L. Antiepileptic drugs and brain development. Epilepsy Res 2010;88:11-22.
50. Turski CA, Ikonomidou C. Neuropathological sequelae of developmental exposure to antiepileptic and anesthetic drugs. Front Neurol 2012;3:120.
51. Galanopoulou AS, Buckmaster PS, Staley KJ, et al. Identification of new epilepsy treatments: Issues in preclinical methodology. Epilepsia 2012;53:571-582.
52. Bhattacharya A, Wang Q, Ao H, et al. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol 2013;170:624-640.
53. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 2002;1:383-386.